申请人:Sankyo Company Limited
公开号:US04572912A1
公开(公告)日:1986-02-25
The compounds of formula (I): ##STR1## [in which: R.sup.1 and R.sup.2 are the same or different and each represents hydrogen or C.sub.1 -C.sub.5 alkyl; R.sup.3 represents hydrogen, an acyl group, a (C.sub.1 -C.sub.6 alkoxy)carbonyl group or an aralkyloxycarbonyl group; R.sup.4 and R.sup.5 are the same or different and each represents hydrogen, C.sub.1 -C.sub.5 alkyl or C.sub.1 -C.sub.5 alkoxy, or R.sup.4 and R.sup.5 together represent a C.sub.1 14 C.sub.4 alkylenedioxy group; n is 1, 2 or 3; W represents the --CH.sub.2 --, >CO or >CH--OR.sup.6 group (in which R.sup.6 represents any one of the atoms or groups defined for R.sup.3 and may be the same as or different from R.sup.3); and Y and Z are the same or different and each represents oxygen or imino] and pharmaceutically acceptable salts thereof have various valuable therapeutic effects on the blood system and may be prepared by a process which includes reacting a corresponding halopropionic acid derivative with thiourea.
式(I)的化合物:##STR1## [其中:R.sup.1和R.sup.2相同或不同,分别代表氢或C.sub.1-C.sub.5烷基;R.sup.3代表氢,酰基,(C.sub.1-C.sub.6烷氧基)羰基或苯基甲氧基羰基;R.sup.4和R.sup.5相同或不同,分别代表氢,C.sub.1-C.sub.5烷基或C.sub.1-C.sub.5烷氧基,或R.sup.4和R.sup.5一起代表C.sub.1-C.sub.4烷二氧基基团;n为1、2或3;W代表--CH.sub.2 --、>CO或>CH--OR.sup.6基团(其中R.sup.6代表R.sup.3定义的任意一个原子或基团,并且可能与R.sup.3相同或不同);Y和Z相同或不同,分别代表氧或亚胺基]及其药学上可接受的盐在血液系统上具有各种有价值的治疗效果,并可通过将相应的卤代丙酸衍生物与硫脲反应制备。